Anaheim spun out of Alesta Therapeutics prior to its recent acquisition by BioMarin

在BioMarin最近收购Alesta Therapeutics之前，Anaheim从Alesta Therapeutics分拆出来

Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital

融资由 Droia Ventures、Frazier Life Sciences、RTW、诺华风险投资基金、RV Invest 和 Thuja Capital 提供

Runway into 2028 with clinic entry in 2027 for ANA-1

ANA-1 将于 2027 年进入临床试验，资金可支撑至 2028 年

LEIDEN, Netherlands

荷兰莱顿

,

，

Nov. 5, 2026

2026年11月5日

/PRNewswire/ -- Anaheim Bio, a preclinical-stage biotechnology company spun out of Alesta Therapeutics, launched today with an oversubscribed €40 million Series A financing to advance ANA-1, a small molecule therapeutic candidate for calcium pyrophosphate deposition disease (CPPD), expected to enter the clinic in 2027..

/美通社/ -- 从Alesta Therapeutics分拆出来的临床前阶段生物技术公司Anaheim Bio今日宣布启动，并完成了超额认购的4,000万欧元A轮融资，以推进ANA-1的研发。ANA-1是一种用于治疗焦磷酸钙沉积病（CPPD）的小分子候选药物，预计将于2027年进入临床试验阶段。

'ANA-1 is designed to directly address the underlying pathology of CPPD and has the potential to change treatment for the millions of people worldwide who today have no therapy that targets the crystal deposits driving the disease,' said Ilan Ganot, Chief Executive Officer of Anaheim Bio. 'This financing takes ANA-1 through IND-enabling studies and into Phase 1.

“ANA-1旨在直接针对CPPD的潜在病理机制，有望改变全球数百万目前缺乏针对驱动疾病的晶体沉积物的靶向疗法患者的治疗现状。”Anaheim Bio首席执行官Ilan Ganot表示。“这笔融资将支持ANA-1完成新药临床试验申请（IND）所需的 enabling 研究，并推进至I期临床试验。”

We are pleased that Alesta's legacy investors are backing us again, a reflection of their confidence in this program and our team.'.

我们很高兴 Alesta 的原有投资者再次支持我们，这体现了他们对本项目及我们团队的信心。

Anaheim Bio's lead program, ANA-1, is a small molecule inhibitor designed to lower extracellular PPi for the treatment of CPPD. CPPD is a form of inflammatory arthritis caused by the accumulation of calcium pyrophosphate crystals in and around the joints. It most commonly affects older adults and can cause sudden, recurrent episodes of severe joint pain and swelling, as well as chronic arthritis.

Anaheim Bio 的核心项目 ANA-1 是一种小分子抑制剂，旨在降低细胞外焦磷酸盐（PPi）水平，用于治疗焦磷酸钙沉积病（CPPD）。CPPD 是一种炎症性关节炎，由焦磷酸钙晶体在关节内及周围积聚引起。该病最常见于老年人，可导致突然、反复发作的严重关节疼痛和肿胀，以及慢性关节炎。

CPPD is estimated to affect approximately 4% to 7% of adults in Europe and the United States. Current treatments focus on controlling inflammation and symptoms, with no approved therapy available to remove or dissolve the underlying crystal deposits..

据估计，CPPD 影响欧洲和美国约 4% 至 7% 的成年人。目前的治疗主要集中在控制炎症和症状上，尚无获批的疗法可用于清除或溶解潜在的晶体沉积物。

'We look forward to work once again with the former Alesta team,' said Luc Dochez, Chair of the Board of Anaheim Bio and Managing Partner at Droia Ventures. 'ANA-1 positions them to go after one of the largest underserved opportunities in rheumatology.'

“我们期待与前Alesta团队再次合作，”阿纳海姆生物公司董事长兼德罗亚风投管理合伙人吕克·多谢表示。“ANA-1使他们能够进军风湿病学领域最大的未满足需求机会之一。”

Anaheim Bio's management team includes Ilan Ganot, Chief Executive Officer; Matthias Van Woensel, Ph.D., Chief Scientific Officer; Rick Dekker, Chief Financial Officer; and Benit Maru, MBChB, Ph.D., Interim Chief Medical Officer.

Anaheim Bio 的管理团队包括首席执行官伊兰·加诺特（Ilan Ganot）、首席科学官马蒂亚斯·范·温塞尔（Matthias Van Woensel）博士、首席财务官里克·德克尔（Rick Dekker），以及临时首席医疗官贝尼特·马鲁（Benit Maru）医学博士、哲学博士。

The Board of Directors includes Luc Dochez (Chair), Droia Ventures; Dan Estes, Ph.D., Frazier Life Sciences; Ilan Ganot, Anaheim Bio; Janwillem Naesens, Droia Ventures, Laura Brass, Ph.D., Novartis Venture Fund and John McHutchison, AO, M.D., who joins as an independent director having previously served as a strategic advisor to Alesta..

董事会成员包括：Luc Dochez（主席，Droia Ventures）；Dan Estes 博士（Frazier Life Sciences）；Ilan Ganot（Anaheim Bio）；Janwillem Naesens（Droia Ventures）；Laura Brass 博士（Novartis Venture Fund）；以及 John McHutchison 医学博士、AO，他以独立董事身份加入，此前曾担任 Alesta 的战略顾问。

About Anaheim Bio

关于安纳海姆生物

Anaheim Bio is a preclinical-stage biotechnology company. Its lead program, a small molecule therapy, is in development for calcium pyrophosphate deposition disease (CPPD). The company was formed in 2026 from programs spun out of Alesta Therapeutics and is backed by Alesta's former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja Capital.

Anaheim Bio 是一家处于临床前阶段的生物技术公司。其核心项目是一种小分子疗法，正在开发用于治疗焦磷酸钙沉积病（CPPD）。该公司成立于2026年，由从 Alesta Therapeutics 剥离的项目组建而成，并得到 Alesta 前投资者的支持，包括 Droia Ventures、Frazier Life Sciences、RTW Investments、诺华风险投资基金（Novartis Venture Fund）、RV Invest 和 Thuja Capital。

Anaheim Bio is based in Leiden, the Netherlands. For more information, visit .

Anaheim Bio 总部位于荷兰莱顿。欲了解更多信息，请访问。

www.anaheimbio.com

www.anaheimbio.com

.

。